Erschienen in:
29.01.2024 | Letter to the Editor
Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction
verfasst von:
Takuro Washio, Sarah L. Hissen, Ryosuke Takeda, John D. Akins, Denis J. Wakeham, Tiffany Brazile, Christopher M. Hearon Jr, James P. MacNamara, Satyam Sarma, Benjamin D. Levine, Paul J. Fadel, Qi Fu
Erschienen in:
Clinical Autonomic Research
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Excerpt
The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) continues its yearly increase in the USA and now surpasses that of HF with reduced ejection fraction (HFrEF) [
9]. HFpEF is associated with high morbidity, mortality, and economic cost. Medications established as part of guideline-directed medical therapy have reduced hospitalization rates and cardiovascular morbidity and mortality for patients with HFrEF [
9]. However, most current drug therapies remain unsuccessful in improving clinical outcomes in patients with HFpEF. Therefore, other pharmacotherapies are urgently needed to effectively treat HFpEF. …